Insight journal - Company

Partnering with Valeant: Partnering for a healthier future

Posted on 07 June 2013

Tags: , ,

Valeant is a top pharma company active in partnering, licensing and M&A in generic pharmaceuticals.

Valeant has a well-defined business development strategy which is focused on growth driven by merger, acquisition and partnering.

Partnering is an important supporting pillar of the overall strategy to supplement and strengthen core pipeline and our position as a late stage and marketed pharmaceuticals leader.

Valeant’s partnering process

Little is disclosed by Valeant about its partnering process, so we have to establish a position using past partnering and M&A activity to suggest an approach of interest to Valeant as follows:

Summary of Valeant’s partnering interests

Valeant’s partnering interests can probably be summarized as follows:

M&A – the company is interested in acquiring companies that provide a complementary match with Valeant’s existing business, making use of or adding to existing infrastructure and product portfolio

Asset purchase – the company is a frequent acquirer of last stage product assets in its primary therapy focus areas

Licensing – the company is a frequent licensee of last stage product assets in its primary therapy focus areas

Distribution/marketing – the company will often exploit distribution and marketing relationships in order to expand market penetration

Therapy focus – recent deal activity suggests a focus on dermatology, central nervous system, oncology and infective diseases.

Partnering outreach

Valeant are less routinely present at partnering events throughout the year when compared to other bigpharma companies. This is probably due to its emphasis on late stage and marketed product opportunities.

For a full list of forthcoming partnering events where you could meet with Valeant in person visit Current Partnering’s Event calendar.

Contacting Valeant for partnering

Valeant can be contacting in relation to partnering through a number of channels.

Here is a list of the most common channels:

Partnering events: face to face contact is generally considered the most effective form of contact. Partnering events not only allow face to face contact but also contact with multiple companies for the price of one flight and hotel reservation. This benefit makes partnering events the most cost effective method of making personal introductions as a start point for partnering discussions.

See Current Partnering’s event calendar for details of forthcoming events.

Direct contact: there are several sources of direct contact with Valeant business development team

- Phone: Picking up the phone and speaking with an individual is the best form of non-face to face contact as it allows your name and voice to be remembered and associated with an opportunity.

-  Email: Sending an email is another good way of making contact. Ideally, research the individual responsible for the therapy/technology area being targeted and get in touch. Valeant do not publish a list of contacts on their website, so unless you cannot find a direct contact elsewhere use the contacts here.

LinkedIn: Business to business contact is increasingly taking place via LinkedIn, the global online networking channel. Many of Valeant business development executives have LinkedIn profiles and can be found by viewing the company’s profile. Visit Valeant LinkedIn page here


Summary profile data for Valeant

Partnering activity for Valeant

M&A activity for Valeant


Available reports from Current Partnering

Report: Partnering Deals and Alliances with Valeant Pharmaceuticals

Report: Partnering Deals and Alliances with Big Pharma


Available resources for deal coverage for Valeant         

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Read: more on Valeant company profile, recent partnering, M&A and financing news and articles



Report: Practical Guide to Finding Partners

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s M&A Scorecard – view top life science M&A deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter - reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk

View: Top 50 biotech – overview of top 50 biotechnology companies by revenue – partnering activity, deal news, partnering dealtalk

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

Print Friendly, PDF & Email

Leave a Reply